© Reuters. FILE PHOTO: An employee of the Bavarian vaccine company Nordic works in the company’s laboratory in Martinsried near Munich, Germany, May 24, 2022. The company, which has its headquarters in Denmark, is the only company World’s largest approved for vacuum smallpox
COPENHAGEN (Reuters) – Spain’s Bavarian Nordic biotech on Wednesday raised its sales outlook and now expects a smaller operating loss this year after signing a deal with a foreign country. undisclosed availability of monkeypox vaccine.
Shares in Bavaria were trading up 16% at 1019 GMT and were up more than 40% since the company announced a similar vaccine supply deal with an undisclosed country on May 19. votes are down 28% this year.
“We have quickly adapted to this unprecedented situation and are working closely with other governments to deliver a vaccine as quickly as possible to mitigate the situation,” said Chief Executive Officer Paul Chaplin. .
The company is currently in discussions with several other countries about potential supply agreements for the Jynneos-branded monkeypox vaccine Imvanex in the United States.
On Tuesday, Germany announced it had ordered 40,000 doses of the Bavarian vaccine, but the company has not confirmed whether it has entered into any agreements with Germany.
Bavarian now expects sales to reach between 1.3 and 1.5 billion Danish crowns ($187-215 million), up from previous estimates between 1.1 and 1.4 billion.
It also raised expectations for earnings before interest, taxes and amortization (EBITDA) to a loss of $1 to 1.2 billion, up from a previous estimate of a loss of 1-1.3 billion.
Global health officials have tracked more than 200 suspected and confirmed cases of the usually mild virus in 19 countries since early May.
(1 dollar = 6.9698 Danish crowns)